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mune responses. We present results of an ongoing Phase I clinical
trial of haplo-mismatched allogeneic stem cell transplant (SCT) sup-
plemented with donor lymphocyte infusions (DLIs) PDT depleted of
host-reactive T cells. Nine high-risk patients with hematologic ma-
lignancies (5 AML relapsed or refractory, 2 MDS, 1 NHL, 1 refrac-
tory CLL) entered the trial, 7 (4 M, 3 F) are evaluable for acute
GVHD and immune reconstitution. Donor mononuclear cells
(MNCs) were incubated with recipient MNCs for 4 days, exposed to
TH9402 PDT, stored frozen, and administered on day 30	3 after
transplant at 3 graded DLI dose levels: 1104 (1pt), 5104 (3pts), and
1.3 105 (3pts) CD3 cells/kg. Anti-host cytotoxic T lymphocyte
precursors (CTLp) were depleted from DLIs by approximately 1.5
logs, and ﬂow cytometry showed greater than 90% elimination of
activated T cells (CD4CD25 and CD8CD25) by TH9402
PDT. Median age at SCT was 57 years (range: 40-58). The myeloa-
blative regimen consisted of TBI (1200 cGy), thiotepa (5 mg/kg) and
ﬂudarabine (40 mg/m2/day for 5 days) followed by infusion of CD3
depleted HSC grafts. No GVHD prophylaxis was administered.
Evaluable patients showed durable trilineage hematologic engraft-
ment and achieved complete donor chimerism. No patient developed
acute GVHD (grade II-IV), while 3 patients developed signs of
chronic GVHD. Two patients died: one (cohort 1) of a post-trans-
plant lymphoproliferative disease, and one (cohort 2), of relapsed
AML. No other patient relapsed. Two pts recovered greater than
0.3109 CD3 and CD4 cells/L at 2 and 5 months post-DLI, and
4 pts had 0.2109 CD3 cells/L at 6 mo post-DLI. Although 4
patients developed infectious complications (HSV, CMV, Nocardia,
Aspergillus), all resolved rapidly with appropriate therapy. The overall
disease-free-survival and survival are 57% at 1 year (median follow-up:
9.4 mo). Our results indicate that the post-transplant infusion of a
PDT treated DLI is feasible, does not induce acute GVHD, and may
accelerate T cell reconstitution.
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Immunotherapy with allodepleted donor T-cells generated using
a CD25 immunotoxin improves immune reconstitution after
haplo-SCT, but leukaemic relapse remains a problem. To develop
a rational approach to reﬁning allodepletion, we characterised the
phenotype of proliferating alloreactive T cells ﬂow cytometrically.
CFSE-labelled T cells were co-cultured with HLA-mismatched
dendritic cells and serial FACS analyses performed to determine
expression of CD25, CD69, CD71, HLA-DR, OX40, ICOS,
CD95, CD45RA, CCR7, IFN, TNF, and IL-2. By staining each
sample with CD3, CFSE and CD25 we were able to determine the
phenotype of proliferating CD25 negative alloreactive T cells. In 5
donors, after a 3 day culture, CD25 was expressed in a mean of 83
% (67-89 %) of the proliferating (CFSE-dim) alloreactive T cells,
conﬁrming CD25 as an excellent target for allodepletion. 70 %
(39-81 %) of the proliferating alloreactive CD25 -ve population
expressed CD71, and 62 % (50-74 %) expressed CD45RA, iden-
tifying these two molecules, as markers of alloreactive T cells that
would be retained after CD25 based allodepletion. We then com-
pared residual alloreactivity after CD25 vs CD25/71 vs CD25/
45RA based allodepletion using negative selection with immuno-
magnetic beads in 5 HLA-mismatched donors-recipient pairs.
Primary MLRs showed a mean residual proliferation to host of
0.58 % (0-2.7 %) after CD25 depletion, 1.73 % (0– 7.6 %) after
CD25/45RA depletion and 0.04 % (0-0.2 %) for CD25/71 deple-
tion. IFN- ELISPOT analyses demonstrated that when recul-
tured with original stimulator, CD25 depletion led to a mean 88 %
reduction in IFN SFC compared to unmanipulated sensitized
PBMCs and this was enhanced by CD25/71 (95 %) or CD25/
45RA depletion (93 %) with third party responses maintained for
all 3 arms. In secondary MLRs, the mean residual proliferations to
the original stimulator was: CD25 allodepletion 0.71 % (0-1.14
%), CD25/CD71 0.01 %, (0-0.04 %) (CD25 vs CD25/71 p0.06)
and for CD25/CD45RA 14.85 % ( 0-33.09 %)(CD25 vs CD25/
45RA p0.028). Studies demonstrating preservation of antiviral
responses after CD25/71 depletion will be presented. We conclude
that CD25/71 allodepletion will selectively delete  90% of the
proliferating alloreactive T cells and enhances the depletion of
alloreactivity compared with CD25-based methods. This strategy
may facilitate immunotherapy with larger doses of allodepleted
donor T-cells after haplo-SCT, enhancing graft versus leukaemia
and antiviral effects.
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Impaired thymopoiesis contributes to immune deﬁciency in ag-
ing, AIDS, and following allogeneic bone marrow transplantation.
Little is known of the mechanisms of thymic regulation. We show
that castration of male mice resulted in increased thymic size,
thymocyte number, intrathymic T cell receptor excision circles,
and the number of early thymic progenitors (ETP: Lin- CKIT hi
CD44 hi) as early as eight days post-castration. These observations
suggested a mechanism of enhanced thymopoieis that occurs
through increased immigration of thymocyte precursors presum-
ably due to increased circulating progenitors. However, the earliest
T cell progenitor population in the bone marrow (LSK: Lin-, c-kit
hi, Sca-1, IL7Ra-) was not increased in castrated mice. In addi-
tion, statistically signiﬁcant increases in thymocyte number and
early thymus subsets occurred on day 5, prior to the increase in
thymic ETPs (day 8). Five days post-castration, there was a statis-
tically signiﬁcant doubling of double negative (DN) thymocytes,
with the greatest increases in the DN3 and DN4 populations.
Double positive (DP) thymocytes (CD4CD8) were signiﬁ-
cantly increased as well. Furthermore, there was evidence of sig-
niﬁcantly increased proliferation of DN3 and increased transit into
DP thymocytes determined by bromodeoxyuridine (BRDU) incor-
poration reﬂected in DN3 and DP thymocytes at this time point.
These data suggest that intrathymic maturation of primitive thy-
mocytes is important early in the mechanism of enhanced thymo-
poiesis following androgen withdrawal. Preliminary data also dem-
onstrate a concomitant increase in the percentage of BRDU 
thymic epithelial cells (TEC) at day5, implicating stromal prolif-
eration in thymic expansion. Immunohistochemistry analyses using
laser scanning cytometery suggest an increase in both cortical and
medullary TEC subsets following castration. Finally, preliminary
adoptive transfer studies with congenic LSK suggest enhanced
uptake of ETP occur after these intrathymic changes. These data
suggest that androgen withdrawal leads to proliferation of thymic
epithelial cell subsets with enhanced maturation of early thymo-
cytes, followed by increased ETP entry into the thymus. These
studies have implications for enhanced thymopoiesis following
marrow transplant and identify two points of thymic regulation: 1)
TEC proliferation and 2) ETP entry into the thymus.
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